Gemopatrilat

Gemopatrilat (INN)[1] is an experimental drug that was never marketed.[2] It acts as a vasopeptidase inhibitor.[3][4] It inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (neprilysin).[5]

Gemopatrilat
Clinical data
Other namesBMS-189921
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC19H26N2O4S
Molar mass378.49 g·mol−1
3D model (JSmol)

References
  1. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 46" (PDF). World Health Organization. p. 200. Retrieved 2 March 2017.
  2. "Gemopatrilat". AdisInsight. Highest Development Phases: Discontinued
  3. Laverman GD, Van Goor H, Henning RH, De Jong PE, De Zeeuw D, Navis G (January 2003). "Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes". Kidney International. 63 (1): 64–71. doi:10.1046/j.1523-1755.2003.00708.x. PMID 12472769.
  4. Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, et al. (June 2006). "Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans". Drug Metabolism and Disposition. 34 (6): 961–70. doi:10.1124/dmd.105.007500. PMID 16540589. S2CID 25629874.
  5. Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM (May 2001). "In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat". Journal of Hypertension. 19 (5): 941–6. doi:10.1097/00004872-200105000-00015. PMID 11393678. S2CID 9162678.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.